Literature DB >> 20696777

Heterogeneous and complex rearrangements of chromosome arm 6q in chondromyxoid fibroma: delineation of breakpoints and analysis of candidate target genes.

Salvatore Romeo1, Ronald A J Duim, Julia A Bridge, Fredrik Mertens, Danielle de Jong, Paola Dal Cin, Pauline M Wijers-Koster, Maria Debiec-Rychter, Raf Sciot, Andrew E Rosenberg, Karoly Szuhai, Pancras C W Hogendoorn.   

Abstract

Chondromyxoid fibroma (CMF) is an uncommon benign cartilaginous tumor of bone usually occurring during the second decade of life. CMF is associated with recurrent rearrangements of chromosome bands 6p23-25, 6q12-15, and 6q23-27. To delineate further the role and frequency of the involvement of three candidate regions (6q13, 6q23.3 and 6q24) in the pathogenesis of CMF, we studied a group of 43 cases using a molecular cytogenetic approach. Fluorescence in situ hybridization with probe sets bracketing the putative breakpoint regions was performed in 30 cases. The expression level of nearby candidate genes was studied by immunohistochemistry and quantitative RT-PCR in 24 and 23 cases, respectively. Whole-genome copy number screening was performed by array comparative genomic hybridization in 16 cases. Balanced and unbalanced rearrangements of 6q13 and 6q23.3 occurred in six and five cases, respectively, and a hemizygous deletion in 6q24 was found in five cases. Two known tumor suppressor genes map to the latter region: PLAGL1 and UTRN. However, neither of these two genes nor BCLAF1 and COL12A1, respectively located in 6q23.3 and 6q13, showed altered expression. Therefore, although rearrangements of chromosomal regions 6q13, 6q23.3, and 6q24 are common in CMF, the complexity of the changes precludes the use of a single fluorescence in situ hybridization probe set as an adjunct diagnostic tool. These data indicate that the genetic alterations in CMF are heterogeneous and are likely a result of a cryptic rearrangement beyond the resolution level of combined binary ratio fluorescence in situ hybridization or a point mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696777      PMCID: PMC2928969          DOI: 10.2353/ajpath.2010.091277

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  The PLAGL1 gene is down-regulated in human extraskeletal myxoid chondrosarcoma tumors.

Authors:  Hugo Poulin; Yves Labelle
Journal:  Cancer Lett       Date:  2005-01-08       Impact factor: 8.679

2.  Chondromyxoid fibroma of the nasal cavity with an interstitial insertion between chromosomes 6 and 19.

Authors:  Cristina A Smith; R Ellen Magenis; Eleanor Himoe; Cheree Smith; Atiya Mansoor
Journal:  Cancer Genet Cytogenet       Date:  2006-12

3.  Interstitial deletion of 6q without phenotypic effect.

Authors:  Kerstin Hansson; Karoly Szuhai; Jeroen Knijnenburg; Arie van Haeringen; Joke de Pater
Journal:  Am J Med Genet A       Date:  2007-06-15       Impact factor: 2.802

Review 4.  Recurrent anomalies of 6q25 in chondromyxoid fibroma.

Authors:  A Safar; M Nelson; J R Neff; G E Maale; J Bayani; J Squire; J A Bridge
Journal:  Hum Pathol       Date:  2000-03       Impact factor: 3.466

5.  Emerin binding to Btf, a death-promoting transcriptional repressor, is disrupted by a missense mutation that causes Emery-Dreifuss muscular dystrophy.

Authors:  Tokuko Haraguchi; James M Holaska; Miho Yamane; Takako Koujin; Noriyo Hashiguchi; Chie Mori; Katherine L Wilson; Yasushi Hiraoka
Journal:  Eur J Biochem       Date:  2004-03

6.  The pericentromeric inversion, inv (6)(p25q13), is a novel diagnostic marker in chondromyxoid fibroma.

Authors:  S R Granter; A A Renshaw; H P Kozakewich; J A Fletcher
Journal:  Mod Pathol       Date:  1998-11       Impact factor: 7.842

Review 7.  Benign cartilaginous tumors of bone: from morphology to somatic and germ-line genetics.

Authors:  Salvatore Romeo; Pancras C W Hogendoorn; Angelo Paolo Dei Tos
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

Review 8.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

9.  Chondromyxoid fibroma of rib with a novel chromosomal translocation: a report of four additional cases at unusual sites.

Authors:  Henry B Armah; Richard L McGough; Mark A Goodman; Susanne M Gollin; Urvashi Surti; Anil V Parwani; Uma N M Rao
Journal:  Diagn Pathol       Date:  2007-11-24       Impact factor: 2.644

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  3 in total

1.  GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma.

Authors:  Karolin H Nord; Henrik Lilljebjörn; Francesco Vezzi; Jenny Nilsson; Linda Magnusson; Johnbosco Tayebwa; Danielle de Jong; Judith V M G Bovée; Pancras C W Hogendoorn; Karoly Szuhai
Journal:  Nat Genet       Date:  2014-03-23       Impact factor: 38.330

2.  GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics.

Authors:  Angus M S Toland; Suk Wai Lam; Sushama Varma; Aihui Wang; Brooke E Howitt; Christian A Kunder; Darcy A Kerr; Karoly Szuhai; Judith V M G Bovée; Gregory W Charville
Journal:  Am J Surg Pathol       Date:  2022-06-01       Impact factor: 6.298

Review 3.  Chondromyxoid Fibroma of the Mastoid: A Rare Entity with Comprehensive Literature Review.

Authors:  Ahmed Elsamanody; Maaike Van den Aardweg; Alexander Smits; Stefan Willems; Vedat Topsakal
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.